Giuseppe Giaccone

Giuseppe Giaccone

Auto-generated profile, based on publicly available information

Giuseppe Giaccone

Meyer Cancer Center, Weill Cornell Medicine , New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FCFabio Conforti
Fabio Conforti
LPLaura Pala
Laura Pala
EPEleonora Pagan
Eleonora Pagan
VBVincenzo Bagnardi
Vincenzo Bagnardi
Tommaso De PasTommaso De Pas
Tommaso De Pas
GGGiuseppe Giaccone
Giuseppe Giaccone
Purpose: We previously demonstrated that sex influences response to immune checkpoint inhibitors. In this article, we investigate sex-based differences in the molecular mechanisms of anticancer immune response and immune evasion in patients with NSCLC. Experimental Design: We analyzed (i) transcriptome data of 2,575 early-stage NSCLCs from seven different datasets; (ii) 327 tumor samples extensively characterized at the molecular level from the TRACERx lung study; (iii) two independent cohorts of 329 and 391 patients, respectively, with advanced NSCLC treated with anti–PD-1/anti–PD-L1 drugs. Results: As compared with men, the tumor microenvironment (TME) of women was significantly enriched for a number of innate and adaptive immune cell types, including specific T-cell subpopulations. NSCLCs of men and women exploited different mechanisms of immune evasion. The TME of females was characterized by significantly greater T-cell dysfunction status, higher expression of inhibitory immune checkpoint molecules, and higher abundance of immune-suppressive cells, including cancer-associated fibroblasts, MDSCs, and regulatory T cells. In contrast, the TME of males was significantly enriched for a T-cell–excluded phenotype. We reported data supporting impaired neoantigens presentation to immune system in tumors of men, as molecular mechanism explaining the findings observed. Finally, in line with our results, we showed significant sex-based differences in the association between TMB and outcome of patients with advanced NSCLC treated with anti–PD-1/PD-L1 drugs. Conclusions: We demonstrated meaningful sex-based differences of anticancer immune response and immune evasion mechanisms, that may be exploited to improve immunotherapy efficacy for both women and men.

2 July 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CKChul Kim
Chul Kim
Stephen LiuStephen Liu
Stephen Liu
DSDeepa S Subramaniam
Deepa S Subramaniam
TTTisdrey Torres
Tisdrey Torres
MLMassimo Loda
Massimo Loda
GGGiuseppe Giaccone
Giuseppe Giaccone
Background: Lutathera is a 177Lutetium-labeled somatostatin analog approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). Somatostatin receptors are expressed in small cell lung cancer (SCLC). Nivolumab, an anti-PD-1 antibody, may act synergistically with lutathera to generate antitumor immunity. We conducted a phase I study of lutathera plus nivolumab in patients with advanced NETs of the lung. Methods: Patients with relapsed/refractory extensive-stage SCLC (ES-SCLC), non-progressing ES-SCLC after first-line platinum-based chemotherapy, or advanced grade I-II pulmonary NETs were eligible. The primary objective was to determine the recommended phase 2 dose (RP2D). The phase I portion followed a standard 3+3 design, assessing two dose levels (dose level 1: lutathera 3.7 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks; dose level 2: lutathera 7.4 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks). Results: Nine patients were enrolled (six ES-SCLC, two pulmonary atypical carcinoid, one high-grade pulmonary neuroendocrine carcinoma). No dose-limiting toxicities (DLTs) were observed at dose level 1. At dose level 2, one patient with refractory ES-SCLC developed a DLT (grade 3 rash). The most common treatment-related adverse events (TRAEs) were lymphopenia (n=7), thrombocytopenia (n=4), anemia (n=3), and nausea (n=3). The most common grade 3 TRAE was lymphopenia (n=4). Among the seven patients with measurable disease, one patient with ES-SCLC had a partial response. Two patients with pulmonary atypical carcinoid had stable disease lasting 6 months. The RP2D was dose level 2. Conclusions: Lutathera plus nivolumab was well tolerated and showed signs of antitumor activity. This combination warrants further exploration. Trial registration number: NCT03325816

1 March 2021 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
GGGiuseppe Giaccone
Giuseppe Giaccone
CKChul Kim
Chul Kim

16 June 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
ATAnish Thomas
Anish Thomas
CMChirayu Mohindroo
Chirayu Mohindroo
GGGiuseppe Giaccone
Giuseppe Giaccone

3 September 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
YHYongfeng He
Yongfeng He
ARArchana Ramesh
Archana Ramesh
YGYuriy Gusev
Yuriy Gusev
KBKrithika Bhuvaneshwar
Krithika Bhuvaneshwar
GGGiuseppe Giaccone
Giuseppe Giaccone
Thymic carcinoma is rare and has a poorer prognosis than thymomas. The treatment options are limited after failure of platinum-based chemotherapy. We previously performed a single-center phase II study of pembrolizumab in patients with advanced thymic carcinoma, showing a 22.5% response rate. Here, we characterize the genomic and transcriptomic profile of thymic carcinoma samples from 10 patients (5 non-responders versus 5 responders) in this cohort, with the main aim of identifying potential predictors of response to immunotherapy. We find that expression of PDL1 and alterations in genes or pathways that correlated with PD-L1 expression (CYLD and BAP1) could be potential predictors for response or resistance to immunotherapy in patients with advanced thymic carcinoma. Our study provides insights into potential predictive markers/pathways to select patients with thymic carcinoma for anti-PD-1 immunotherapy.

19 May 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
YHYumin Han
Yumin Han
TLTrevor Lee
Trevor Lee
YHYongfeng He
Yongfeng He
RRRenuka Raman
Renuka Raman
AIAdriana Irizarry
Adriana Irizarry
GGGiuseppe Giaccone
Giuseppe Giaccone